These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 21251615)

  • 1. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
    Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
    Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors.
    Shim J; Huang A; Miller AS
    J Immunol Methods; 2017 Sep; 448():26-33. PubMed ID: 28506821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
    Li F; Ravetch JV
    Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
    Richman LP; Vonderheide RH
    Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
    Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
    Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
    White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
    J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
    Li F; Ravetch JV
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10966-71. PubMed ID: 22723355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
    Waight JD; Chand D; Dietrich S; Gombos R; Horn T; Gonzalez AM; Manrique M; Swiech L; Morin B; Brittsan C; Tanne A; Akpeng B; Croker BA; Buell JS; Stein R; Savitsky DA; Wilson NS
    Cancer Cell; 2018 Jun; 33(6):1033-1047.e5. PubMed ID: 29894690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).
    Medler J; Wajant H
    Methods Mol Biol; 2021; 2248():81-90. PubMed ID: 33185869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
    Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE
    Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
    White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
    Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
    Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
    Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
    Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
    Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
    MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
    Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
    Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.